Consulting and advising for preclinical epilepsy and neurological disease drug discovery
We provide insight and validated solutions to inform safety and efficacy assessment for epilepsy.
Start a conversation
Led by Dr. Melissa Barker-Haliski
Associate Professor, University of Washington
Therapies supported
Cannabidiol (Epidiolex) - 2018
This study established the preclinical profile of cannabidiol in a range of validated rodent seizure and epilepsy models, including maximal electroshock, 6 Hz, and corneal kindled mouse models. It provided the pivotal preclinical data to position canabidiol as a novel therapeutic strategy for epilepsy.
Learn moreFenfluramine (Fintepla) - 2019
This study provided the preclinical assessment of the anticonvulsant activity of fenfluramine when administered acutely in three mouse models of acute and chronic seizures: the maximal electroshock (MES) test, the 6 Hz 44 mA test, and the corneal kindled mouse. Fenfluramine exerted dose-related anticonvulsant effect in the mouse maximal electroshock test, a validated rodent model of tonic-clonic seizures in humans.
Learn moreSoticlestat (in Phase III) - 2023
Soticlestat is a novel inhibitor of the brain-specific cholesterol 24-hydroxylase enzyme, which has been implicated in the progression of several neurological diseases. This study assessed the disease-modifying effect of repeated soticlestat administration in a mouse acquired seizure model following brain infection with Theiler's virus.
Learn more